Cosmos Health enters the US market with a Dolcas Biotech deal
Cosmos Health (cosm) announced the launch of a US-based manufacturing industry through an entry into the US market and a strategic agreement with Dolcas Biotech LLC, a New Jersey developer and manufacturer of clinically researched dietary supplements. Cosmos Health is set to begin production in the US at its GMP-certified facility, marking an important milestone in expanding the company’s operations. This movement does not only ease Customs Exposure and cross-border logistics risks will place Cosmos to strengthen production control beyond the existing European footprint and scale efficiently in the global healthcare market, the statement said. Greg Siokas, CEO of Cosmos Health, said: “We are proud to reach this important milestone as we begin production in the US through an agreement with Dolcas Biotech, a partner who is widely acknowledged in its commitment to quality and innovation. Changing trade dynamics.”
First published fly – The ultimate source of financial news that moves to the market in real time. Try it now >>
See today’s best performance stocks in Tipranks >>
Read more about COSM: